Navigation Links
Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Date:6/11/2008

Lead Candidate Set for Phase II Clinicals

LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today that it has been granted an exclusive, worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs for the treatment of heart failure. The most advanced drug in the portfolio is expected to enter a Phase II clinical study later this year.

The drug portfolio was developed in part by Jonathan S. Stamler, M.D., George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University, and Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology and Director of the Interdisciplinary Stem Cell Institute at University of Miami. Dr. Hare was formerly associated with Johns Hopkins University.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

According to the National Heart, Lung and Blood Institute (NHLBI), there are an estimated five million Americans that suffer from congestive heart failure, a condition characterized by the inability of the heart to efficiently pump blood and by fluid accumulation in the lungs and other tissues. An estimated 300,000 deaths each y
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
4. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
5. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... 8, 2007--The World Health Organization,has released new ... rising in,Pakistan. , So is this another ... pharmaceutical industry is denying important vaccines to,poor ... to London’s Guardian,newspaper, “parents of 24,000 children ...
... clinical development program of first-in-class CB1,antagonist rimonabant to ... life-style drug , BARCELONA, Spain | March 08, ... reported today that Sanofi-Aventis’,first-in-class CB1 antagonist Acomplia (rimonabant) ... to phase III and many more,in earlier phases ...
Cached Medicine Technology:Why Is Polio Spreading in Pakistan? 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... type 2 diabetes is dramatically increasing throughout the world. ... and it most often precedes the onset of hyperglycemia ... thiazolidinediones (TZD), the agonists of the peroxisome proliferators-activated receptor ... in the liver, adipose tissue, and skeletal muscle, thus ...
... Gordon HealthDay Reporter , MONDAY, March 14 (HealthDay ... medications for type 2 diabetes, an older drug -- metformin ... new analysis of research on diabetes medications. The ... that all of them lower blood sugar levels by a ...
... 15 (HealthDay News) -- Having a bad, short-term or poorly ... having no job, according to a new study. Researchers ... in Australia and were not surprised to find that those ... with jobs. However, the study authors also found that ...
... A nursing home industry is booming in China ... elderly population forces a nationwide shift from traditional family ... Brown University gerontologists. The study, led by Zhanlian ... in the Journal of the American Geriatrics Society ...
... If all eligible patients filled their prescriptions through a $4 ... $6 billion, according to a University of Pittsburgh Graduate School ... issue of Archives of Internal Medicine , the study ... a broad use of discounted generic medication programs that are ...
... -- The benefits of bariatric (weight loss) surgery may ... to a new scientific statement from the American Heart ... absorption of food as it passes through the ... person,s caloric intake. The statement-writing committee reviewed ...
Cached Medicine News:Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 3Health News:Bad Job May Be Worse for Mental Health Than No Job at All 2Health News:Nursing home boom in China has little government involvement 2Health News:Nursing home boom in China has little government involvement 3Health News:Use of $4 generic drug programs could save society billions of dollars, study shows 2Health News:Benefits of Weight-Loss Surgery May Outweigh Risks for Some, Experts Say 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: